ARCT - Arcturus Therapeutics Holdings Inc Stock Price, Fair Value and News

$6.58+0.33 (+5.28%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ARCT Price Action

Last 7 days

-3.2%

Last 30 days

-29.2%

Last 90 days

-60.7%

Trailing 12 Months

-63.2%

ARCT RSI Chart

ARCT Valuation

Market Cap

187.0M

Price/Earnings (Trailing)

-2.8

Price/Sales (Trailing)

1.92

EV/EBITDA

0.79

Price/Free Cashflow

-3.19

ARCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

97.6M

Rev. Growth (Yr)

-58.84%

Rev. Growth (Qtr)

-39.4%

ARCT Earnings

Earnings (TTM)

-66.7M

Earnings Growth (Yr)

-94.81%

Earnings Growth (Qtr)

-46.49%

ARCT Profitability

EBT Margin

-68.35%

Return on Equity

-29.71%

Return on Assets

-23.63%

Free Cashflow Yield

-31.37%

ARCT Investor Care

Shares Dilution (1Y)

4.89%

Diluted EPS (TTM)

-2.45

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	143.7M	122.1M	97.6M	0
2024	124.5M	163.9M	160.4M	152.3M
2023	281.0M	264.5M	296.2M	166.8M
2022	15.5M	40.6M	51.5M	206.0M
2021	9.0M	8.7M	8.8M	12.4M
2020	19.1M	11.3M	10.3M	9.5M
2019	17.0M	18.3M	19.5M	20.8M
2018	0	0	0	15.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.

CEO	Mr. Joseph E. Payne M.Sc.
WEBSITE	https://arcturusrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	170

Arcturus Therapeutics Holdings Inc Frequently Asked Questions

What is the ticker symbol for Arcturus Therapeutics Holdings Inc? What does ARCT stand for in stocks?

ARCT is the stock ticker symbol of Arcturus Therapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Wed Dec 03 2025, market cap of Arcturus Therapeutics Holdings Inc is 186.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers.

Is Arcturus Therapeutics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ARCT is over valued or under valued. Whether Arcturus Therapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Arcturus Therapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARCT.

What is Arcturus Therapeutics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ARCT's PE ratio (Price to Earnings) is -2.8 and Price to Sales (PS) ratio is 1.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Arcturus Therapeutics Holdings Inc's stock?

In the past 10 years, Arcturus Therapeutics Holdings Inc has provided -0.171 (multiply by 100 for percentage) rate of return.